102 related articles for article (PubMed ID: 22149091)
1. Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer.
Ellinger J; Kahl P; von der Gathen J; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Bastian PJ; von Ruecker A; Müller SC; Rogenhofer S
Cancer Invest; 2012 Feb; 30(2):92-7. PubMed ID: 22149091
[TBL] [Abstract][Full Text] [Related]
2. Global levels of histone modifications predict prostate cancer recurrence.
Ellinger J; Kahl P; von der Gathen J; Rogenhofer S; Heukamp LC; Gütgemann I; Walter B; Hofstädter F; Büttner R; Müller SC; Bastian PJ; von Ruecker A
Prostate; 2010 Jan; 70(1):61-9. PubMed ID: 19739128
[TBL] [Abstract][Full Text] [Related]
3. Global histone modification patterns predict risk of prostate cancer recurrence.
Seligson DB; Horvath S; Shi T; Yu H; Tze S; Grunstein M; Kurdistani SK
Nature; 2005 Jun; 435(7046):1262-6. PubMed ID: 15988529
[TBL] [Abstract][Full Text] [Related]
4. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.
Deligezer U; Yaman F; Darendeliler E; Dizdar Y; Holdenrieder S; Kovancilar M; Dalay N
Clin Chim Acta; 2010 Oct; 411(19-20):1452-6. PubMed ID: 20573596
[TBL] [Abstract][Full Text] [Related]
5. Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer.
Ellinger J; Bachmann A; Göke F; Behbahani TE; Baumann C; Heukamp LC; Rogenhofer S; Müller SC
Urol Int; 2014; 93(1):113-8. PubMed ID: 24556868
[TBL] [Abstract][Full Text] [Related]
6. Re: Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.
Zhu Y; Ye D
Clin Chim Acta; 2010 Dec; 411(23-24):2117. PubMed ID: 20831865
[No Abstract] [Full Text] [Related]
7. JMJD3 is a histone H3K27 demethylase.
Xiang Y; Zhu Z; Han G; Lin H; Xu L; Chen CD
Cell Res; 2007 Oct; 17(10):850-7. PubMed ID: 17923864
[TBL] [Abstract][Full Text] [Related]
8. Cancer: a changing global view.
Marte B
Nature; 2005 Jun; 435(7046):1172. PubMed ID: 15988507
[No Abstract] [Full Text] [Related]
9. Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma.
Rogenhofer S; Kahl P; Mertens C; Hauser S; Hartmann W; Büttner R; Müller SC; von Ruecker A; Ellinger J
BJU Int; 2012 Feb; 109(3):459-65. PubMed ID: 21810159
[TBL] [Abstract][Full Text] [Related]
10. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy.
Compérat E; Rouprêt M; Drouin SJ; Camparo P; Bitker MO; Houlgatte A; Cancel-Tassin G; Cussenot O
Prostate; 2010 Nov; 70(15):1622-7. PubMed ID: 20687232
[TBL] [Abstract][Full Text] [Related]
11. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
[TBL] [Abstract][Full Text] [Related]
12. Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.
Shiota M; Song Y; Yokomizo A; Tada Y; Kuroiwa K; Eto M; Oda Y; Inokuchi J; Uchiumi T; Fujimoto N; Seki N; Naito S
Endocr Relat Cancer; 2010 Jun; 17(2):455-67. PubMed ID: 20308360
[TBL] [Abstract][Full Text] [Related]
13. Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma.
Rogenhofer S; Kahl P; Holzapfel S; VON Ruecker A; Mueller SC; Ellinger J
Anticancer Res; 2012 Mar; 32(3):879-86. PubMed ID: 22399607
[TBL] [Abstract][Full Text] [Related]
14. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma.
Park YS; Jin MY; Kim YJ; Yook JH; Kim BS; Jang SJ
Ann Surg Oncol; 2008 Jul; 15(7):1968-76. PubMed ID: 18470569
[TBL] [Abstract][Full Text] [Related]
15. Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer.
Caso JR; Tsivian M; Mouraviev V; Polascik TJ; Moul JW
BJU Int; 2010 Dec; 106(11):1623-7. PubMed ID: 20553260
[TBL] [Abstract][Full Text] [Related]
16. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Miyake H; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Urol Oncol; 2010; 28(2):145-51. PubMed ID: 18848789
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
Bastian PJ; Ellinger J; Heukamp LC; Kahl P; Müller SC; von Rücker A
Eur Urol; 2007 Mar; 51(3):665-74; discussion 674. PubMed ID: 16956712
[TBL] [Abstract][Full Text] [Related]
18. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
20. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
Jones TD; Koch MO; Lin H; Cheng L
BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
